Skip to main content

Advertisement

Table 2 QPCR analysis of selected miRNAs in arterial FFPE samples from T2DM and Non-DM patients

From: No detectable differential microRNA expression between non-atherosclerotic arteries of type 2 diabetic patients (treated or untreated with metformin) and non-diabetic patients

microRNA Assay nr. References T2DM n = 26 Non-DM n = 26 P T2DM (− Met) n = 11 Non-DM n = 26 P T2DM (+ Met) n = 15 T2DM (− Met) n = 11 P
Mean ± SD Mean ± SD Mean ± SD Mean ± SD Mean ± SD Mean ± SD
miR-21-5p 397 [37] 0.112 ± 0.079 0.101 ± 0.098 0.928 − 0.012 ± 0.098 0.101 ± 0.098 0.493 0.204 ± 0.117 − 0.012 ± 0.090 0.183
miR-24-3p 402 [29, 30] 0.123 ± 0.093 0.100 ± 0.114 0.876 − 0.099 ± 0.114 0.100 ± 0.114 0.303 0.286 ± 0.126 − 0.099 ± 0.114 0.039
miR-26a-5p 405 [31] 0.120 ± 0.071 0.116 ± 0.096 0.978 − 0.018 ± 0.096 0.116 ± 0.096 0.408 0.220 ± 0.095 − 0.018 ± 0.095 0.097
miR-182-3p 483 [32] 1.215 ± 0.264 (n = 10) 1.449 ± 0.179 (n = 17) 0.456 1.037 ± 0.179 (n = 5) 1.449 ± 0.179 (n = 17) 0.326 1.393 ± 0.297 (n = 5) 1.037 ± 0.457 (n = 5) 0.532
miR-145-5p 2278 [33, 34] 0.134 ± 0.088 0.107 ± 0.109 0.846 − 0.067 ± 0.109 0.107 ± 0.109 0.346 0.281 ± 0.121 − 0.067 ± 0.103 0.047
miR-29a-3p 2112 [12,13,14,15,16,17] 0.158 ± 0.075 0.180 ± 0.084 0.849 0.064 ± 0.084 0.180 ± 0.084 0.434 0.227 ± 0.105 0.064 ± 0.104 0.294
miR-29b-3p 413 [12,13,14,15,16,17] 0.150 ± 0.091 0.220 ± 0.087 0.582 0.017 ± 0.087 0.220 ± 0.087 0.240 0.247 ± 0.102 0.017 ± 0.160 0.216
miR-221-5p 2096 [28] NA NA NA NA NA NA
miR-222-5p 2097 [28] 0.246 ± 0.118 (n = 25) 0.306 ± 0.084 0.674 − 0.135 ± 0.084 (n = 10) 0.306 ± 0.084 0.011 0.499 ± 0.134 − 0.135 ± 0.154 (n = 10) 0.006
miR-132-3p 457 [35] 0.123 ± 0.090 0.189 ± 0.105 0.636 − 0.040 ± 0.105 0.189 ± 0.105 0.231 0.242 ± 0.108 − 0.040 ± 0.144 0.122
miR-212-3p 515 [35] − 0.072 ± 0.043 − 0.013 ± 0.075 0.501 − 0.122 ± 0.075 − 0.013 ± 0.075 0.358 − 0.035 ± 0.072 − 0.122 ± 0.028 0.326
miR-1298-5p 2861 [36] − 0.099 ± 0.041 0.035 ± 0.070 0.104 − 0.222 ± 0.070 0.035 ± 0.070 0.031 − 0.009 ± 0.047 − 0.222 ± 0.054 0.007
  1. For each of the 12 miRNAs three patient group comparisons were made: T2DM vs. non-DM patients; non-metformin-treated T2DM (− Met) vs. non-DM patients; and non-metformin-treated T2DM (− Met) vs. metformin-treated T2DM patients (+ Met). Normalization was performed using equal amounts of total RNA for each sample and by normalizing the relative expression to the synthetic miRNA ath-miR-159a. Values are mean ± SD. Assay nr. refers to TaqMan microRNA assays (Life Technologies)